<unk>  is a nucleoside analog reverse transcriptase inhibitors that is FDA approved for the treatment of HIV-1 infection. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include dizziness, headache, insomnia, abnormal dreams, skin rash, diarrhea, vomiting, nausea, abdominal pain, gastroenteritis, infection, weakness, otitis media, cough, rhinitis, pneumonia, and fever.
Emtricitabine and tenofovir alafenamide fumarate
Emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide fumarate
Efavirenz, emtricitabine and tenofovir disoproxil fumarate
Emtricitabine and tenofovir disoproxil fumarate
Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide
Bictegravir / emtricitabine / tenofovir alafenamide
Bictegravir sodium, emtricitabine, tenofovir alafenamide fumarate
Dolutegravir / rilpivirine